NRX Pharmaceuticals, Inc. (NRXP): M&A transaction — NRx subsidiary HOPE Therapeutics completes acquisition of Dura Medical

NRX Pharmaceuticals, Inc.

Dura Medical is revenue generating and EBITDA positive; operates clinics in Naples and Ft. Myers.
Offers ketamine therapy, TMS, Spravato, stellate ganglion blocks for depression and PTSD.
Participates in VA Community Cares Network; founder Stephen Durand appointed Director of Florida Clinic Operations.
Combined with pending acquisitions to provide coverage at more than 8 locations on Florida's West Coast.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

NRX Pharmaceuticals, Inc. completed an acquisition involving Dura Medical, LLC for a combination of cash, membership interests in HTX Management Company LLC (which are convertible into shares of Hope Therapeutics on a one-for-one basis at the (closed 2025-09-08).

Action: acquisition
Counterparty: Dura Medical, LLC
Consideration: a combination of cash, membership interests in HTX Management Company LLC (which are convertible into shares of Hope Therapeutics on a one-for-one basis at the
Closing: 2025-09-08

Exact text from the filing

On September 8, 2025, NRx Pharmaceuticals (NASDAQ: NRXP, or the “Company”), principally through its subsidiary HOPE Therapeutics, Inc., a Delaware corporation, completed its previously announced acquisition of Dura Medical, LLC

View on SEC.gov

Browse all m&a transactions →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-028949

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.